DDInter1382 DDInter1397
Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use.
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Palonosetron {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Paroxetine
Palonosetron {u} (Compound) causes {v} (Side Effect) Anaphylactoid reaction
Anaphylactoid reaction {u} (Side Effect) is caused by {v} (Compound) Paroxetine
Palonosetron {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is associated with {v} (Disease) endogenous depression
endogenous depression {u} (Disease) is palliated by {v} (Compound) Paroxetine
Palonosetron {u} (Compound) resembles {v} (Compound) Praziquantel
Praziquantel {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Paroxetine
Palonosetron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Paroxetine
Palonosetron {u} (Compound) resembles {v} (Compound) Praziquantel
Praziquantel {u} (Compound) downregulates {v} (Gene) CSRP1
CSRP1 {u} (Gene) is downregulated by {v} (Compound) Paroxetine
Palonosetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ezogabine
Ezogabine {u} (Compound) causes {v} (Side Effect) Ill-defined disorder
Ill-defined disorder {u} (Side Effect) is caused by {v} (Compound) Paroxetine
Palonosetron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} (Compound) causes {v} (Side Effect) Erythema multiforme
Erythema multiforme {u} (Side Effect) is caused by {v} (Compound) Paroxetine
Palonosetron {u} (Compound) resembles {v} (Compound) Praziquantel
Praziquantel {u} (Compound) causes {v} (Side Effect) Malaise
Malaise {u} (Side Effect) is caused by {v} (Compound) Paroxetine
Palonosetron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Sulfamethoxazole {u} (Compound) downregulates {v} (Gene) RPS4Y1
RPS4Y1 {u} (Gene) is downregulated by {v} (Compound) Paroxetine
Palonosetron (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Paroxetine (Compound)
Palonosetron (Compound) causes Anaphylactoid reaction (Side Effect) and Anaphylactoid reaction (Side Effect) is caused by Paroxetine (Compound)
Palonosetron (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is associated with endogenous depression (Disease) and endogenous depression (Disease) is palliated by Paroxetine (Compound)
Palonosetron (Compound) resembles Praziquantel (Compound) and Praziquantel (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Paroxetine (Compound)
Palonosetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Paroxetine (Compound)
Palonosetron (Compound) resembles Praziquantel (Compound) and Praziquantel (Compound) downregulates CSRP1 (Gene) and CSRP1 (Gene) is downregulated by Paroxetine (Compound)
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine and Ezogabine (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Paroxetine (Compound)
Palonosetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Paroxetine (Compound)
Palonosetron (Compound) resembles Praziquantel (Compound) and Praziquantel (Compound) causes Malaise (Side Effect) and Malaise (Side Effect) is caused by Paroxetine (Compound)
Palonosetron may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Paroxetine (Compound)